• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SCIEX Sets a New Standard in Accurate Mass Quantitation With the ZenoTOF 8600 System and New Software Collaborations

    6/2/25 7:00:00 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials
    Get the next $DHR alert in real time by email

    At ASMS 2025, SCIEX, a global leader in life science analytical technologies and operating company of Danaher Corporation (NYSE:DHR), launches the ZenoTOF 8600 system, setting a new standard in accurate mass quantitation. The system is competitive in identification, superior in quantitation, and enhances structural understanding so scientists can now confidently quantify thousands of species from complex samples in short acquisition times.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250602013425/en/

    SCIEX launches the ZenoTOF 8600 system.

    SCIEX launches the ZenoTOF 8600 system.

    The ZenoTOF 8600 system brings sensitive quantitation and decades of SCIEX leadership in triple quad innovation to the ZenoTOF portfolio. Innovations include:

    • The OptiFlow Pro source, DJet ion guide, and QJet ion guide – Enables the system to generate and transmit more ions. When combined with the Zeno trap, this facilitates 10x improvement in sensitivity, compared to the ZenoTOF 7600+ system.
    • Mass Guard technology, introduced last year on the SCIEX 7500+ system – Protects the system from contamination and increases uptime.
    • New optical detector – Allows the system to operate effectively at higher ion currents.
    • ZT Scan DIA 2.0 – Covers a larger mass range so scientists can now quantify what was previously a struggle to identify – across all omics disciplines. ZT Scan DIA 2.0 is a transformation of the most comprehensive SCIEX DIA approach.

    "The ZenoTOF 8600 system gives you the resolution and speed you need, but the sensitivity allows us to do everything on one box. We are not just seeing more things, we are identifying them, and at times 30-40% more. And because of ZT Scan DIA 2.0, there is this additional treasure of information that has increased our capacity to discover new things, which we were not anticipating. It's the first time I've been able to do nominal mass resolution on the precursor, which finally allows us to do SWATH type of analysis on lipids or complex natural products," said Dr. Nicola Zamboni, Ph.D., Principal investigator and adjunct professor at the Institute of Molecular Systems Biology of ETH Zurich. "As a result, these abilities enhance our capacity in discovery biology. They deepen our understanding of mechanisms. They help us find things that matter."

    To match the data processing needs of the ZenoTOF 8600 system, the new SCIEX OS software version 4.0 enhances operability with speed and automation. Automated workflow improvements and progressive software functionalities establish the benchmark for efficiency, accuracy, and precision.

    This builds on the SCIEX OS ecosystem, to seamlessly connect innovations in hardware and software processing. A new software collaboration this year includes that with MS-Dial, an open-source software platform designed for untargeted metabolomics and lipidomics analysis. This collaboration enhances the identification and quantification of small molecules through advanced spectral deconvolution and library matching. The latest version of MS-Dial now supports SCIEX raw data across multiple scan modes and is well-suited for ZT Scan DIA, ensuring greater accuracy and efficiency in data analysis.

    In addition, SCIEX and Bioinformatics Solutions Inc (BSI) continue to drive innovation in mass spectrometry-based proteomics solutions. The latest release of PEAKS Studio 13 translates data from ZT Scan DIA, SWATH DIA, and DDA to deliver expansive peptide identification, reliable protein inference, and novel peptides, as well as deep insight into the PTM and sequence variant expression within biological studies. This version also brings processing improvements for ZT Scan DIA, optimizing CV% and processing speed to ensure greater accuracy and efficiency in proteomics workflows.

    "This year's launches will enable us to see exciting impact across OMICS research. We are motivated by what our customers tell us, that they can foresee real-world outcomes as a result of the new data generated and the insights interpreted," Jose Castro-Perez Ph.D., Vice president, product management at SCIEX.

    To learn more about the ZenoTOF 8600 system, visit https://sciex.com/products/mass-spectrometers/qtof-systems/8600-system.

    About SCIEX

    SCIEX empowers our customers to solve the most impactful analytical challenges in quantitation and characterization. With groundbreaking innovation and outstanding reliability and support, SCIEX has been at the forefront of the field for over 50 years. ​

    Since the launch of the first-ever commercially successful triple quadrupole in 1981, we continue to develop technologies and solutions that influence life-changing research and outcomes. That's why thousands of life science experts around the world choose SCIEX to get the answers they can trust. ​

    Advances in human wellness depend on the power of precise science.​

    For more information, visit sciex.com. ​

    Connect with us on LinkedIn, Facebook, X (Twitter) and Instagram.​

    SCIEX is proud to be part of Danaher. ​

    Danaher's science and technology leadership puts SCIEX solutions at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers. Together with Danaher's other businesses across Biotechnology, Diagnostics and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day.

    The SCIEX clinical diagnostic portfolio is for in vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to www.sciex.com/diagnostics. All other products are For Research Use Only. Not for use in Diagnostic Procedures.

    Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries (see www.sciex.com/trademarks).

    © 2025 DH Tech. Dev. Pte. Ltd. MKT-35293-A.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250602013425/en/

    Lulu VanZandt

    Senior manager, brand, public relations and social media

    [email protected]

    M: +1 (508) 782-9484

    Get the next $DHR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DHR

    DatePrice TargetRatingAnalyst
    4/10/2025$205.00Equal Weight → Overweight
    Barclays
    3/21/2025$260.00Neutral → Buy
    Goldman
    3/14/2025$260.00Hold → Buy
    Stifel
    2/3/2025Outperform → Mkt Perform
    Raymond James
    12/23/2024Sector Perform
    Scotiabank
    12/19/2024$275.00Buy
    Guggenheim
    12/13/2024$290.00Neutral → Buy
    BofA Securities
    10/31/2024$285.00Peer Perform → Outperform
    Wolfe Research
    More analyst ratings

    $DHR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Software Launches for SCIEX OS Ecosystem to Help Scientists Accelerate Discoveries and Streamline Lab Operations

      SCIEX, a global leader in life science analytical technologies and operating company of Danaher Corporation (NYSE:DHR), announces three software ecosystem enhancements at ASMS. These developments will present new ways to acquire data, new standards for performance, and new practices to extract elevated insights, all supporting the theme that "all science is data science now." The new SCIEX OS software version 4.0 is the latest evolution of its powerful software platform. This new Microsoft Windows 11 compatible release drives operability enhancements with speed and automation to improve customers' time to results. SCIEX OS 4.0 delivers advanced hardware support for the latest SCIEX inno

      6/2/25 7:00:00 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • SCIEX Sets a New Standard in Accurate Mass Quantitation With the ZenoTOF 8600 System and New Software Collaborations

      At ASMS 2025, SCIEX, a global leader in life science analytical technologies and operating company of Danaher Corporation (NYSE:DHR), launches the ZenoTOF 8600 system, setting a new standard in accurate mass quantitation. The system is competitive in identification, superior in quantitation, and enhances structural understanding so scientists can now confidently quantify thousands of species from complex samples in short acquisition times. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250602013425/en/SCIEX launches the ZenoTOF 8600 system. The ZenoTOF 8600 system brings sensitive quantitation and decades of SCIEX leadership in

      6/2/25 7:00:00 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • SCIEX and Evosep expand access to standardized proteomics for Pharma and Biotech with new reseller agreement

      SCIEX, a global leader in life science analytical technologies and operating company of Danaher Corporation (NYSE:DHR), and Evosep Biosystems, a global leader in proteomics solutions, enter a reseller agreement to co-sell SCIEX mass spectrometry systems with the newly announced Evosep Eno, for standardized high-throughput proteomics. The reseller agreement empowers researchers to implement standardized proteomics workflows, delivering a robust LC-MS solution designed to meet the evolving demands of pharmaceutical and biotech companies. With Evosep Eno, researchers gain exceptional throughput, sensitivity, and reproducibility. When combined with SCIEX mass spectrometers—engineered for spee

      6/2/25 7:00:00 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials

    $DHR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Stevens Raymond C was granted 577 shares, increasing direct ownership by 5% to 12,361 units (SEC Form 4)

      4 - DANAHER CORP /DE/ (0000313616) (Issuer)

      5/19/25 5:02:20 PM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • Director Spoon Alan G was granted 577 shares, increasing direct ownership by 0.48% to 121,308 units (SEC Form 4)

      4 - DANAHER CORP /DE/ (0000313616) (Issuer)

      5/19/25 5:02:10 PM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • Director Schwieters John T was granted 577 shares, increasing direct ownership by 3% to 17,096 units (SEC Form 4)

      4 - DANAHER CORP /DE/ (0000313616) (Issuer)

      5/19/25 5:01:57 PM ET
      $DHR
      Industrial Machinery/Components
      Industrials

    $DHR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Danaher Corporation (Amendment)

      SC 13G/A - DANAHER CORP /DE/ (0000313616) (Subject)

      2/9/23 11:16:32 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • SEC Form SC 13G/A filed by Danaher Corporation (Amendment)

      SC 13G/A - DANAHER CORP /DE/ (0000313616) (Subject)

      2/9/22 3:43:35 PM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • SEC Form SC 13D/A filed by Danaher Corporation (Amendment)

      SC 13D/A - DANAHER CORP /DE/ (0000313616) (Subject)

      11/2/21 9:29:29 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials

    $DHR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Danaher upgraded by Barclays with a new price target

      Barclays upgraded Danaher from Equal Weight to Overweight and set a new price target of $205.00

      4/10/25 8:28:29 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • Danaher upgraded by Goldman with a new price target

      Goldman upgraded Danaher from Neutral to Buy and set a new price target of $260.00

      3/21/25 8:01:35 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • Danaher upgraded by Stifel with a new price target

      Stifel upgraded Danaher from Hold to Buy and set a new price target of $260.00

      3/14/25 7:34:47 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials

    $DHR
    Financials

    Live finance-specific insights

    See more
    • Danaher Announces Quarterly Dividend

      WASHINGTON, May 6, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.32 per share of its common stock, payable on July 25, 2025 to holders of record on June 27, 2025. ABOUT DANAHERDanaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses and h

      5/6/25 4:15:00 PM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • Danaher Reports First Quarter 2025 Results

      WASHINGTON, April 22, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) (the "Company") today announced results for the quarter ended March 28, 2025. Key First Quarter 2025 Results Net earnings were $1.0 billion, or $1.32 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $1.88.Revenues decreased 1.0% to $5.7 billion and non-GAAP core revenue was flat year-over-year.Operating cash flow was $1.3 billion and non-GAAP free cash flow was $1.1 billion.Rainer M. Blair, President and Chief Executive Officer, stated, "Revenue, earnings, and cash flow exceeded our expectations in the first quarter–highlighted by continued momentum in bioprocessing and better-

      4/22/25 6:00:00 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • Danaher Schedules First Quarter 2025 Earnings Conference Call

      WASHINGTON, March 20, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2025 on Tuesday, April 22, 2025 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call. You

      3/20/25 4:15:00 PM ET
      $DHR
      Industrial Machinery/Components
      Industrials

    $DHR
    Leadership Updates

    Live Leadership Updates

    See more
    • Danaher Announces Appointment of Charles Lamanna to Danaher Board

      WASHINGTON, Feb. 20, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced today that it has appointed Charles Lamanna to its Board of Directors and to the Board's Science & Technology Committee. Mr. Lamanna is currently Corporate Vice President, Business & Industry Copilot at Microsoft (NASDAQ:MSFT), where he drives product innovation in AI-powered business applications, low-code platforms, and autonomous agents. He oversees the design, product development, and engineering of some of Microsoft's most transformative technologies, including Power Platform, Dynamics 365, and Copilot Studio. Prior to that, Mr. Lamanna was the founder and CEO of MetricsHub, one of the first public cloud

      2/20/25 4:45:00 PM ET
      $DHR
      $MSFT
      Industrial Machinery/Components
      Industrials
      Computer Software: Prepackaged Software
      Technology
    • Compass Minerals Announces Senior Leadership Team Appointments

      Patrick Merrin named Chief Operations Officer and Peter Fjellman named Chief Financial Officer Compass Minerals (NYSE:CMP), a leading global provider of essential minerals, today announced the appointment of Patrick Merrin, a seasoned operating executive in the mining industry, as the company's new chief operations officer (COO) and Peter Fjellman, who has decades of experience in senior finance roles, as its new chief financial officer (CFO). Merrin's appointment is effective March 3 and fills the COO position which has been open since June 2024. Fjellman, whose appointment is effective immediately, succeeds Jeff Cathey who has decided to depart Compass Minerals due to personal reasons.

      1/28/25 6:50:00 AM ET
      $CMP
      $DHR
      $GXO
      $XPO
      Mining & Quarrying of Nonmetallic Minerals (No Fuels)
      Industrials
      Industrial Machinery/Components
      Transportation Services
    • Danaher Announces Two New Centers of Innovation in Diagnostics to Transform Precision Medicine Development

      DH Diagnostics LLC Centers aim to accelerate drug development by speeding and streamlining development and commercialization of companion diagnostics.Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP)-certified laboratories will bring technologies and assays from multiple Danaher subsidiaries together under a single roof.WASHINGTON, July 17, 2024 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) ("Danaher"), a global science and technology innovator, announced the launch of two new Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP)-certified labs intended to accelerate the development of Companion Diagnostics (C

      7/17/24 7:30:00 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials

    $DHR
    SEC Filings

    See more
    • SEC Form SD filed by Danaher Corporation

      SD - DANAHER CORP /DE/ (0000313616) (Filer)

      5/12/25 4:39:59 PM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • Danaher Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - DANAHER CORP /DE/ (0000313616) (Filer)

      5/8/25 4:36:17 PM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • Danaher Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - DANAHER CORP /DE/ (0000313616) (Filer)

      4/22/25 6:08:20 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials